New app aims to help veterans taper opioids safely
NCT ID NCT04746833
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study developed and tested a mobile website called LIMIT to help veterans on long-term opioid therapy safely reduce their opioid use while managing chronic pain. 44 veterans participated, using either the LIMIT app or a pain diary app. The goal was to see if the tool is acceptable and helps lower opioid doses.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- SUMMIT web-based application for pain self-management
- What this could lead to
- If successful, this tool could provide a scalable way to help veterans taper off opioids while still managing their pain effectively.
- What could go wrong
- This is a small pilot study with only 44 participants, so results may not apply broadly. The tool's effectiveness and safety need further testing in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
44 people
The number who actually took part.
- Started
-
Mar 2021
- Finished
-
Nov 2023
- Lead sponsor
-
A government agency
The lead sponsor is a US federal agency other than the NIH.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Inclusion criteria for Veterans will be primary care patients who are dispensed 84 consecutive days of a stable dose of opioids (reflecting three consecutive 28-day prescriptions) through primary care and who report stable levels of pain intensity over the past month. Exclusion Criteria: Exclusion criteria will be Veterans on liquid methadone or buprenorphine for opioid use disorder (OUD) and those who have transitioned to buprenorphine (transdermal or sublingual) for chronic pain, have hearing or visual impairments (not corrected with hearing aids or glasses), psychiatric conditions, cognitive impairments, or participating in a concurrent pain or opioid-related research study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic pain are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Philadelphia, Pennsylvania, 19104, United States
-
VA Central Western Massachusetts Healthcare System, Leeds, MA
Leeds, Massachusetts, 01053-9764, United States
-
VA Connecticut Healthcare System West Haven Campus, West Haven, CT
West Haven, Connecticut, 06516-2770, United States
-
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah, 84148-0001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can difficulty naming emotions shape how much tailbone pain you feel?
- Can talk therapy rewire the brain to ease burn Survivors' pain?
- Can a video game teach cancer patients to tame their pain?
- Could a wearable zapper quiet cirrhosis pain without drugs?
- Can ketamine boost mindfulness therapy for people facing pain and PTSD?
- Can virtual walking trick the brain into easing chronic pain?